Dogmas and Controversies in Hematologic Malignancies: West Coast Symposium
This CME-accredited activity, Dogmas and Controversies in Hematologic Malignancies: West Coast Symposium, features leading experts in hematologic malignancies who will provide a comprehensive overview of current and emerging strategies for the management of Hodgkin and non-Hodgkin lymphoma, chronic lymphocytic leukemia, acute leukemias, myeloproliferative neoplasms and multiple myeloma.
The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies. The program features in-depth discussion and analysis of recent advances along with scientific debates and panel-based discussions focusing on controversies in the management of hematologic malignancies. Expert faculty will aim to place the role of different therapeutic agents in a clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care. This conference will highlight a multidisciplinary approach and the integration of new advances in patient-centered care. Physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals will be updated on the the latest updates in Hematologic Malignancies.
- Cancer care professionals
- Practicing medical oncologists/hematologists
- Radiation oncologists
- Medical oncology and hematology fellows
- Oncology nurses
- Nurse practitioners
- Physician assistants
Binay Shah, MD, MHA - Binaytara Foundation
Alexey Danilov, MD, PHD- City of Hope
Thomas Martin, MD- UCSF Helen Diller Medical Center
Vinod Pullarkat MD- City of Hope
The Westin San Diego Gaslamp Quarter
Booking Link: https://book.passkey.com/go/BinaytaraFoundation
Upon successful completion of this educational activity, participants will be able to:
- Review strategies for initial therapy and therapies for relapsed disease for patients with various hematologic malignancies
- Outline efficacy and toxicities of small molecule inhibitors, monoclonal antibodies, antibody drug conjugates, T-cell redirecting bispecific antibodies, and CAR-T for the treatment of patients with hematologic malignancies
- Apply an individualized treatment plan for patients with ALL, AML, CML, MPN, MM, NHL, HL, based on patient- and disease-related factors
- Review evolving role of autologous and allogeneic stem cell transplantation in different hematologic malignancies
GLOBAL ONCOLOGY PROJECT
Click this link to learn more about our ongoing project building a 200-bed cancer hospital in Nepal: https://binayfoundation.org/cancer-hospital/
DAY 1 - March 29th, 2023
All times are listed in Pacific Time (PT)
01:00 PM – 02:00 PM Registration/Networking/Exhibits
02:00 PM – 02:15 PM Welcome
02:15 PM – 03:45 PM Session I- Non-Hodgkin Lymphoma
Session Chair: Alexey Danilov, MD, PHD & Krish Patel, MD
02:15 PM- 02:35 PM Mantle Cell Lymphoma: Is it trying to become CLL?- Tycel Phillips, MD
02:35 PM – 02: 50 PM DLBCL – shifting landscape in 1st and 2nd line
02:50 PM - 03:05 PM What is new in indolent NHL (FL, MZL)? - Geoffrey Shouse, DO, PhD
03:05 PM - 03: 25 PM Debate: CAR T versus bi-Specifics in DLBCL- Mazyar Shadman, MD & Krish Patel, MD
03:25 PM - 03:45 PM- Panel Discussion
03:45 PM – 04:00 PM Break
04:00 PM – 05:30 PM Session II- Leukemia
Session Chair: Vinod Pullarkat, MD
04:00 PM- 04:20 PM- Does anyone still need 7+ 3? Optimal use of venetoclax regimens in AML- Gabriel Mannis, MD
04:20 PM- 04:40 PM- The challenge of TP53 mutated AML- Brian Ball, MD
04:40 PM- 05:00 PM- Therapy related leukemias: Is it all bad news?- Vinod Pullarkat, MD
05:00 PM- 05:20 PM- Treatment milestones and treatment free remission in CML- Neil Shah, MD, PhD
05:20 PM- 05:30 PM: Panel discussion
05:30 PM – 06:30 PM Reception/Networking
DAY 2 - March, 30th, 2024
7:00 AM – 8:00 AM: Registration/ networking/ exhibiting
08:00 AM – 09:30 AM Session III- Myeloma
09:30 AM – 10:00 AM Break
10:00 AM – 11:30 AM Session IV- Leukemia
Session Chair: Vinod Pullarkat, MD
10:00 AM- 10:15 AM- Myeloproliferative neoplasms: Sequencing novel agents and stem cell transplantation
10:15 AM- 10:30 AM- High risk MDS: Anything better than azacytidine?- Bart Scott, MD
10:30 AM- 10:45 AM- Ethnic variability and socioeconomic barriers to acute leukemia therapy- Elisa Quiroz, MD
10:45 AM- 11:15 AM- Debate: Consolidation therapy for ALL in the not so young adult, Immunotherapy vs. Stem Cell Transplantation- Ibrahim Aldoss, MD & Lori Muffly, MD, MS
11:15 AM- 11:30 AM- Panel Discussion
11:30 AM – 12:00 PM Session V- Global Oncology
Improving Access to Hematology and Oncology in LMIC- Binaytara Foundation's Approach- Binay Shah, MD
12:00 PM – 01:00 PM: Lunch
01:00 PM – 02:30 PM Session VI- Myeloma
02:30 PM – 03:00 PM Break
03:00 PM – 04:30 PM Session VII- Hodgkin Lymphoma and CLL
Session Chair: Alexey Danilov, MD, PHD
03:00 PM- 03:20 PM How I treat HL- Ranjana Advani, MD
03:20 PM- 03:35 PM Pathogenesis of Richters syndrome- Lili Wang, MD, PhD
03:35 PM- 03:55 PM Debate 1: BTKi versus BCL2i in frontline therapy of CLL- Bita Fakhri, MD, MPH & Michael Choi, MD
03:55 PM- 04:15 PM Debate 2: POST-BTKi: Future belongs to Non-covalents and Degraders; Future belongs to Bi-specifics and cell therapy- Tanya Siddiqi, MD & Catherine Coombs, MD
04:15 PM- 04:30 PM Panel Discussion
04:30 PM Adjourn
IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:
All conflict of interest has been identified and mitigated for individuals in control of contents.
PLANNING COMMITTEE DISCLOSURE STATEMENT:
None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.
Tanya Siddiqi, Medical Director of Lymphoma City of Hope Orange County, Associate Professor, Director of CLL program, Department of Hematology & Hematopoietic Cell Transplantation
- 9.50 ABIM MOC IISuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 9.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 9.50 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 9.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 9.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 9.50 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 9.50 Contact Hours.
POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE:
All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place.
The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference. The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees.
If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.
Violating this policy will result in a fine equivalent to a general display fee for that conference.
NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:
If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:
- If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
- If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event.
- If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event.
Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.
You may cancel your enrollment at any time. Cancellation fees apply as below:
- 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
- No refunds will be issued if registration is canceled after that date.
No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.